Amgen, Inc. (AMGN)’s Drug Trial Fails To Live Up To Expectation

Shares of Amgen, Inc. (NASDAQ:AMGN), which are up almost 16% this year, were trending high in the early afternoon hours, gaining nearly 4% after a day that saw them topple following negative study results. It appears as though investors are now less concerned about the failed trail because the company said the positive results obtained earlier this month would be sufficient to support submissions for regulatory approvals around the world. On CNBC, Yaron Werber, senior biotech analysts at Citi Investment Research, weighed in on the failed study and what lies ahead for the company.

Amgen, Inc. (NASDAQ:AMGN)

Amgen, Inc. (NASDAQ:AMGN) reported that a study of its drug Kyprolis, for a type of blood cancer, failed to help patients live longer compared to the standard care. The study focused on patients with an advanced case of the blood cancer condition known as multiple myeloma. The drug is approved in the U.S., but the company needed survival evidence to obtain approval in Europe.

Coming on to the case of Amgen, Inc. (NASDAQ:AMGN) and the failure of Kyprolis to improve survival rates, Werber said all is not lost for the company because it already has study results that are good enough for approval.

“This is one of the main reasons why Amgen quite earned it. To put it into perspective, they’ve had another study that was successful recently for the drug that will get approved. But overall, if you look at the profile of this drug Kyrolis  myeloma, which is a blood cancer, the overall profile is probably not quite with originally expected, and we think maybe numbers are going to come down,” he said.

He also talked about Amgen, Inc. (NASDAQ:AMGN)’s journey into developing treatment for myeloma and the marketing opportunity for Kyrolis. He noted that the market is there, but the challenge is that patients keep advancing to better drugs that can keep them alive.

“The market is sizable and continues to grow, and as you know, unfortunately, patients with cancer die, and they always progress from one drug to the next [...],” said Werber.

Disclosure: none

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Top 10 Highest Paying Jobs in the World

Most Expensive Day-Care in New York City

The 10 Cheapest Places to Retire Abroad

Top 10 Most Expensive Luxury Cars in the World – 2014

Killer Small Business Ideas

The 50 Best Personal Finance Blogs

Most Expensive Apartments in New York City

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!